139 related articles for article (PubMed ID: 30676111)
1. Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma.
Philbrick BD; Adamson DC
Expert Opin Investig Drugs; 2019 Mar; 28(3):207-216. PubMed ID: 30676111
[TBL] [Abstract][Full Text] [Related]
2. Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
Cloughesy TF; Petrecca K; Walbert T; Butowski N; Salacz M; Perry J; Damek D; Bota D; Bettegowda C; Zhu JJ; Iwamoto F; Placantonakis D; Kim L; Elder B; Kaptain G; Cachia D; Moshel Y; Brem S; Piccioni D; Landolfi J; Chen CC; Gruber H; Rao AR; Hogan D; Accomando W; Ostertag D; Montellano TT; Kheoh T; Kabbinavar F; Vogelbaum MA
JAMA Oncol; 2020 Dec; 6(12):1939-1946. PubMed ID: 33119048
[TBL] [Abstract][Full Text] [Related]
3. Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma.
Accomando WP; Rao AR; Hogan DJ; Newman AM; Nakao A; Alizadeh AA; Diehn M; Diago OR; Gammon D; Haghighi A; Gruber HE; Jolly DJ; Ostertag D
Clin Cancer Res; 2020 Dec; 26(23):6176-6186. PubMed ID: 32816892
[TBL] [Abstract][Full Text] [Related]
4. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
Cloughesy TF; Landolfi J; Vogelbaum MA; Ostertag D; Elder JB; Bloomfield S; Carter B; Chen CC; Kalkanis SN; Kesari S; Lai A; Lee IY; Liau LM; Mikkelsen T; Nghiemphu P; Piccioni D; Accomando W; Diago OR; Hogan DJ; Gammon D; Kasahara N; Kheoh T; Jolly DJ; Gruber HE; Das A; Walbert T
Neuro Oncol; 2018 Sep; 20(10):1383-1392. PubMed ID: 29762717
[TBL] [Abstract][Full Text] [Related]
5. Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
Huang TT; Hlavaty J; Ostertag D; Espinoza FL; Martin B; Petznek H; Rodriguez-Aguirre M; Ibañez CE; Kasahara N; Gunzburg W; Gruber HE; Pertschuk D; Jolly DJ; Robbins JM
Cancer Gene Ther; 2013 Oct; 20(10):544-51. PubMed ID: 23969884
[TBL] [Abstract][Full Text] [Related]
6. Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Yagiz K; Huang TT; Lopez Espinoza F; Mendoza D; Ibañez CE; Gruber HE; Jolly DJ; Robbins JM
Neuro Oncol; 2016 Oct; 18(10):1390-401. PubMed ID: 27166379
[TBL] [Abstract][Full Text] [Related]
7. Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.
Huang TT; Parab S; Burnett R; Diago O; Ostertag D; Hofman FM; Espinoza FL; Martin B; Ibañez CE; Kasahara N; Gruber HE; Pertschuk D; Jolly DJ; Robbins JM
Hum Gene Ther; 2015 Feb; 26(2):82-93. PubMed ID: 25419577
[TBL] [Abstract][Full Text] [Related]
8. Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.
Mitchell LA; Lopez Espinoza F; Mendoza D; Kato Y; Inagaki A; Hiraoka K; Kasahara N; Gruber HE; Jolly DJ; Robbins JM
Neuro Oncol; 2017 Jul; 19(7):930-939. PubMed ID: 28387849
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.
Cloughesy TF; Landolfi J; Hogan DJ; Bloomfield S; Carter B; Chen CC; Elder JB; Kalkanis SN; Kesari S; Lai A; Lee IY; Liau LM; Mikkelsen T; Nghiemphu PL; Piccioni D; Walbert T; Chu A; Das A; Diago OR; Gammon D; Gruber HE; Hanna M; Jolly DJ; Kasahara N; McCarthy D; Mitchell L; Ostertag D; Robbins JM; Rodriguez-Aguirre M; Vogelbaum MA
Sci Transl Med; 2016 Jun; 8(341):341ra75. PubMed ID: 27252174
[TBL] [Abstract][Full Text] [Related]
10. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Ostertag D; Amundson KK; Lopez Espinoza F; Martin B; Buckley T; Galvão da Silva AP; Lin AH; Valenta DT; Perez OD; Ibañez CE; Chen CI; Pettersson PL; Burnett R; Daublebsky V; Hlavaty J; Gunzburg W; Kasahara N; Gruber HE; Jolly DJ; Robbins JM
Neuro Oncol; 2012 Feb; 14(2):145-59. PubMed ID: 22070930
[TBL] [Abstract][Full Text] [Related]
11. Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients.
Hogan DJ; Zhu JJ; Diago OR; Gammon D; Haghighi A; Lu G; Das A; Gruber HE; Jolly DJ; Ostertag D
Clin Cancer Res; 2018 Oct; 24(19):4680-4693. PubMed ID: 29945998
[No Abstract] [Full Text] [Related]
12. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study.
Watanabe K; Kanaya H; Fujiyama Y; Kim P
Acta Neurochir (Wien); 2002 Dec; 144(12):1265-70; discussion 1270. PubMed ID: 12478337
[TBL] [Abstract][Full Text] [Related]
13. A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models.
Yagiz K; Rodriguez-Aguirre ME; Lopez Espinoza F; Montellano TT; Mendoza D; Mitchell LA; Ibanez CE; Kasahara N; Gruber HE; Jolly DJ; Robbins JM
Mol Ther Oncolytics; 2018 Mar; 8():14-26. PubMed ID: 29322091
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas.
Miller CR; Williams CR; Buchsbaum DJ; Gillespie GY
Cancer Res; 2002 Feb; 62(3):773-80. PubMed ID: 11830532
[TBL] [Abstract][Full Text] [Related]
15. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.
Wong ET; Hess KR; Gleason MJ; Jaeckle KA; Kyritsis AP; Prados MD; Levin VA; Yung WK
J Clin Oncol; 1999 Aug; 17(8):2572-8. PubMed ID: 10561324
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.
Tang P; Roldan G; Brasher PM; Fulton D; Roa W; Murtha A; Cairncross JG; Forsyth PA
J Neurooncol; 2006 Jul; 78(3):311-6. PubMed ID: 16710748
[TBL] [Abstract][Full Text] [Related]
17. DNX-2401: an investigational drug for the treatment of recurrent glioblastoma.
Philbrick B; Adamson DC
Expert Opin Investig Drugs; 2019 Dec; 28(12):1041-1049. PubMed ID: 31726894
[No Abstract] [Full Text] [Related]
18. Chemotherapy for high-grade gliomas.
Galanis E; Buckner J
Br J Cancer; 2000 Apr; 82(8):1371-80. PubMed ID: 10780513
[No Abstract] [Full Text] [Related]
19. Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
Holdhoff M; Ye X; Supko JG; Nabors LB; Desai AS; Walbert T; Lesser GJ; Read WL; Lieberman FS; Lodge MA; Leal J; Fisher JD; Desideri S; Grossman SA; Wahl RL; Schiff D
Neuro Oncol; 2017 Jun; 19(6):845-852. PubMed ID: 28371832
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
